نتایج جستجو برای: selective estrogen receptor modulators

تعداد نتایج: 788619  

Journal: :Cancer research 2002
Helen Brady Sonal Desai Leah M Gayo-Fung Sak Khammungkhune Jeffrey A McKie Eoin O'Leary Laura Pascasio May Kung Sutherland David W Anderson Shripad S Bhagwat Bernd Stein

We have compared the antitumor activities of SP500263, a novel next-generation selective estrogen receptor modulator (SERM), tamoxifen, and raloxifene side-by-side in in vitro and in vivo MCF-7 breast cancer models. In vitro, SP500263 acted as an antiestrogen and potently inhibited estrogen-dependent MCF-7 proliferation with IC(50) values in the nanomolar range. SP500263 also strongly inhibited...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2001
A Howell

Selective estrogen receptor modulators (SERMs) may act as estrogens or antiestrogens depending on the cell and tissue targets. The triphenylethylene SERMs are represented by tamoxifen and toremifene and a new agent with a novel carboxylic acid side chain (GW5638). Because of isomerization in the triphenylethylene molecule, "fixed ring" SERMs were introduced. The major one in development is the ...

Journal: :Frontiers in bioscience 2010
Mohit Sachdeva Yin-Yuan Mo

Several hormones are well known for their role in tumorigenesis. Among them estrogen is the best characterized hormone. In particular, stromal tissue-produced estrogen plays a key role in breast tumor development and progression, highlighting the importance of communications between stromal tissue and tumor cells in the tumor microenvironment. In this review, we update our current understanding...

Journal: :Journal of molecular endocrinology 2011
María Angeles Arevalo María Santos-Galindo Natalia Lagunas Iñigo Azcoitia Luis M Garcia-Segura

Selective estrogen receptor modulators (SERMs), used for the treatment of breast cancer, osteoporosis, and menopausal symptoms, affect the nervous system. Some SERMs trigger neuroprotective mechanisms and reduce neural damage in different experimental models of neural trauma, brain inflammation, neurodegenerative diseases, cognitive impairment, and affective disorders. New SERMs with specific a...

Journal: :Endocrine-related cancer 2015
Suzanne E Wardell Erik R Nelson Christina A Chao Holly M Alley Donald P McDonnell

Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains a first-line treatment for estrogen receptor 1 (ESR1) positive breast cancer. However, tumor resistance limits the duration of response. The clinical efficacy of fulvestrant, a selective ER degrader (SERD) that triggers receptor degradation, has confirmed that ESR1 often remains engaged in endocrine therapy resistant cancers....

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید